APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceutical CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Radiopharmaceutical CDMO Market Analysis and Forecast 2026-2032

16 April 2026242 pages

Choose your research edition.

Industry ResearchRadiopharmaceutical CDMO Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceutical CDMO Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Radiopharmaceutical CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceutical CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceutical CDMO Market Analysis and Forecast 2026-2032242 pages · $4,950 USD

Market perspective

The global Radiopharmaceutical CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Radiopharmaceutical CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Radiopharmaceutical CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Radiopharmaceutical CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Radiopharmaceutical CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Radiopharmaceutical CDMO include Almac, AtomVie, Cardinal Health, Cyclotek, Eckert & Ziegler, Seibersdorf Labor GmbH, Evergreen Theragnostics, Lantheus and Medi-Radiopharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Radiopharmaceutical CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Radiopharmaceutical CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Radiopharmaceutical CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceutical CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Radiopharmaceutical CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Radiopharmaceutical CDMO revenue, projected growth trends, production technology, application and end-user industry.

Radiopharmaceutical CDMO Segment by Company

Almac

AtomVie

Cardinal Health

Cyclotek

Eckert & Ziegler

Seibersdorf Labor GmbH

Evergreen Theragnostics

Lantheus

Medi-Radiopharma

Minerva Imaging

NorthStar

ROTOP Pharmaka GmbH

Nucleus RadioPharma

PharmaLogic

Radiopharmaceutical CDMO Segment by Type

R&D CDMO

Production CDMO

Radiopharmaceutical CDMO Segment by Application

Diagnosis

Treatment

Radiopharmaceutical CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Radiopharmaceutical CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Radiopharmaceutical CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiopharmaceutical CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. R&D CDMO Major Player Table 3. Production CDMO Major Player Table 4. Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Diagnosis Major Player Table 6. Treatment Major Player Table 7. Radiopharmaceutical CDMO Industry Trends Table 8. Radiopharmaceutical CDMO Industry Drivers Table 9. Radiopharmaceutical CDMO Industry Opportunities and Challenges Table 10. Radiopharmaceutical CDMO Industry Restraints Table 11. Global Radiopharmaceutical CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Radiopharmaceutical CDMO Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Radiopharmaceutical CDMO Market Share by Region (2021-2026) Table 14. Global Radiopharmaceutical CDMO Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Radiopharmaceutical CDMO Market Share by Region (2027-2032) Table 16. Global Radiopharmaceutical CDMO Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Radiopharmaceutical CDMO Revenue Market Share by Players (2021-2026) Table 18. Global Radiopharmaceutical CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Radiopharmaceutical CDMO Key Players Headquarters & Area Served Table 20. Global Radiopharmaceutical CDMO Players, Product Type & Application Table 21. Global Radiopharmaceutical CDMO Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Radiopharmaceutical CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Radiopharmaceutical CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Radiopharmaceutical CDMO Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Radiopharmaceutical CDMO Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Radiopharmaceutical CDMO Revenue Market Share by Type (2021-2026) Table 28. Global Radiopharmaceutical CDMO Revenue Market Share by Type (2027-2032) Table 29. Global Radiopharmaceutical CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Radiopharmaceutical CDMO Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Radiopharmaceutical CDMO Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Radiopharmaceutical CDMO Revenue Market Share by Application (2021-2026) Table 33. Global Radiopharmaceutical CDMO Revenue Market Share by Application (2027-2032) Table 34. Almac Company Information Table 35. Almac Business Overview Table 36. Almac Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Almac Radiopharmaceutical CDMO Product Portfolio Table 38. Almac Recent Development Table 39. AtomVie Company Information Table 40. AtomVie Business Overview Table 41. AtomVie Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. AtomVie Radiopharmaceutical CDMO Product Portfolio Table 43. AtomVie Recent Development Table 44. Cardinal Health Company Information Table 45. Cardinal Health Business Overview Table 46. Cardinal Health Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Cardinal Health Radiopharmaceutical CDMO Product Portfolio Table 48. Cardinal Health Recent Development Table 49. Cyclotek Company Information Table 50. Cyclotek Business Overview Table 51. Cyclotek Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Cyclotek Radiopharmaceutical CDMO Product Portfolio Table 53. Cyclotek Recent Development Table 54. Eckert & Ziegler Company Information Table 55. Eckert & Ziegler Business Overview Table 56. Eckert & Ziegler Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Eckert & Ziegler Radiopharmaceutical CDMO Product Portfolio Table 58. Eckert & Ziegler Recent Development Table 59. Seibersdorf Labor GmbH Company Information Table 60. Seibersdorf Labor GmbH Business Overview Table 61. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Portfolio Table 63. Seibersdorf Labor GmbH Recent Development Table 64. Evergreen Theragnostics Company Information Table 65. Evergreen Theragnostics Business Overview Table 66. Evergreen Theragnostics Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Evergreen Theragnostics Radiopharmaceutical CDMO Product Portfolio Table 68. Evergreen Theragnostics Recent Development Table 69. Lantheus Company Information Table 70. Lantheus Business Overview Table 71. Lantheus Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Lantheus Radiopharmaceutical CDMO Product Portfolio Table 73. Lantheus Recent Development Table 74. Medi-Radiopharma Company Information Table 75. Medi-Radiopharma Business Overview Table 76. Medi-Radiopharma Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Medi-Radiopharma Radiopharmaceutical CDMO Product Portfolio Table 78. Medi-Radiopharma Recent Development Table 79. Minerva Imaging Company Information Table 80. Minerva Imaging Business Overview Table 81. Minerva Imaging Radiopharmaceutical CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Minerva Imaging Radiopharmaceutical CDMO Product Portfolio Table 83. Minerva Imaging Recent Development Table 84. NorthStar Company Information Table 85. NorthStar Business Overview Table 86. NorthStar Radiopharmaceutical CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. NorthStar Radiopharmaceutical CDMO Product Portfolio Table 88. NorthStar Recent Development Table 89. ROTOP Pharmaka GmbH Company Information Table 90. ROTOP Pharmaka GmbH Business Overview Table 91. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Portfolio Table 93. ROTOP Pharmaka GmbH Recent Development Table 94. Nucleus RadioPharma Company Information Table 95. Nucleus RadioPharma Business Overview Table 96. Nucleus RadioPharma Radiopharmaceutical CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Nucleus RadioPharma Radiopharmaceutical CDMO Product Portfolio Table 98. Nucleus RadioPharma Recent Development Table 99. PharmaLogic Company Information Table 100. PharmaLogic Business Overview Table 101. PharmaLogic Radiopharmaceutical CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. PharmaLogic Radiopharmaceutical CDMO Product Portfolio Table 103. PharmaLogic Recent Development Table 104. North America Radiopharmaceutical CDMO Revenue by Type (2021-2026) & (US$ Million) Table 105. North America Radiopharmaceutical CDMO Revenue by Type (2027-2032) & (US$ Million) Table 106. North America Radiopharmaceutical CDMO Revenue by Application (2021-2026) & (US$ Million) Table 107. North America Radiopharmaceutical CDMO Revenue by Application (2027-2032) & (US$ Million) Table 108. North America Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America Radiopharmaceutical CDMO Revenue by Country (2021-2026) & (US$ Million) Table 110. North America Radiopharmaceutical CDMO Revenue by Country (US$ Million) & (2027-2032) Table 111. Europe Radiopharmaceutical CDMO Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe Radiopharmaceutical CDMO Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe Radiopharmaceutical CDMO Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Radiopharmaceutical CDMO Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe Radiopharmaceutical CDMO Revenue by Country (2021-2026) & (US$ Million) Table 117. Europe Radiopharmaceutical CDMO Revenue by Country (US$ Million) & (2027-2032) Table 118. China Radiopharmaceutical CDMO Revenue by Type (2021-2026) & (US$ Million) Table 119. China Radiopharmaceutical CDMO Revenue by Type (2027-2032) & (US$ Million) Table 120. China Radiopharmaceutical CDMO Revenue by Application (2021-2026) & (US$ Million) Table 121. China Radiopharmaceutical CDMO Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Radiopharmaceutical CDMO Revenue by Type (2021-2026) & (US$ Million) Table 123. Asia Radiopharmaceutical CDMO Revenue by Type (2027-2032) & (US$ Million) Table 124. Asia Radiopharmaceutical CDMO Revenue by Application (2021-2026) & (US$ Million) Table 125. Asia Radiopharmaceutical CDMO Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Radiopharmaceutical CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia Radiopharmaceutical CDMO Revenue by Region (US$ Million) & (2021-2026) Table 128. Asia Radiopharmaceutical CDMO Revenue by Region (US$ Million) & (2027-2032) Table 129. SAMEA Radiopharmaceutical CDMO Revenue by Type (2021-2026) & (US$ Million) Table 130. SAMEA Radiopharmaceutical CDMO Revenue by Type (2027-2032) & (US$ Million) Table 131. SAMEA Radiopharmaceutical CDMO Revenue by Application (2021-2026) & (US$ Million) Table 132. SAMEA Radiopharmaceutical CDMO Revenue by Application (2027-2032) & (US$ Million) Table 133. SAMEA Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. SAMEA Radiopharmaceutical CDMO Revenue by Country (2021-2026) & (US$ Million) Table 135. SAMEA Radiopharmaceutical CDMO Revenue by Country (US$ Million) & (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Radiopharmaceutical CDMO Image Figure 2. Global Radiopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceutical CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. R&D CDMO Image Figure 5. Production CDMO Image Figure 6. Global Radiopharmaceutical CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Radiopharmaceutical CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Diagnosis Image Figure 9. Treatment Image Figure 10. Global Radiopharmaceutical CDMO Market Size (US$ Million) & (2021-2032) Figure 11. Global Radiopharmaceutical CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Radiopharmaceutical CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Radiopharmaceutical CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Radiopharmaceutical CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Radiopharmaceutical CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Radiopharmaceutical CDMO Revenue Market Share by Type (2021-2032) Figure 18. Global Radiopharmaceutical CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Radiopharmaceutical CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Radiopharmaceutical CDMO Revenue Market Share by Application (2021-2032) Figure 21. North America Radiopharmaceutical CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Radiopharmaceutical CDMO Revenue Share by Type (2021-2032) Figure 23. North America Radiopharmaceutical CDMO Revenue Share by Application (2021-2032) Figure 24. North America Radiopharmaceutical CDMO Revenue Share by Country (2021-2032) Figure 25. United States Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Radiopharmaceutical CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Radiopharmaceutical CDMO Revenue Share by Type (2021-2032) Figure 30. Europe Radiopharmaceutical CDMO Revenue Share by Application (2021-2032) Figure 31. Europe Radiopharmaceutical CDMO Revenue Share by Country (2021-2032) Figure 32. Germany Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Radiopharmaceutical CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Radiopharmaceutical CDMO Revenue Share by Type (2021-2032) Figure 42. China Radiopharmaceutical CDMO Revenue Share by Application (2021-2032) Figure 43. Asia Radiopharmaceutical CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Radiopharmaceutical CDMO Revenue Share by Type (2021-2032) Figure 45. Asia Radiopharmaceutical CDMO Revenue Share by Application (2021-2032) Figure 46. Asia Radiopharmaceutical CDMO Revenue Share by Region (2021-2032) Figure 47. Japan Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Radiopharmaceutical CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Radiopharmaceutical CDMO Revenue Share by Type (2021-2032) Figure 55. SAMEA Radiopharmaceutical CDMO Revenue Share by Application (2021-2032) Figure 56. SAMEA Radiopharmaceutical CDMO Revenue Share by Country (2021-2032) Figure 57. Brazil Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Radiopharmaceutical CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • R&D CDMO
  • Production CDMO
Applications
  • Diagnosis
  • Treatment
Companies covered
  • Almac
  • AtomVie
  • Cardinal Health
  • Cyclotek
  • Eckert & Ziegler
  • Seibersdorf Labor GmbH
  • Evergreen Theragnostics
  • Lantheus
  • Medi-Radiopharma
  • Minerva Imaging
  • NorthStar
  • ROTOP Pharmaka GmbH
  • Nucleus RadioPharma
  • PharmaLogic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Radiopharmaceutical CDMO Market by Type
  3. 1.2.1 Global Radiopharmaceutical CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 R&D CDMO
  5. 1.2.3 Production CDMO
  6. 1.3 Radiopharmaceutical CDMO Market by Application
  7. 1.3.1 Global Radiopharmaceutical CDMO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Diagnosis
  9. 1.3.3 Treatment
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Radiopharmaceutical CDMO Market Dynamics
  1. 2.1 Radiopharmaceutical CDMO Industry Trends
  2. 2.2 Radiopharmaceutical CDMO Industry Drivers
  3. 2.3 Radiopharmaceutical CDMO Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceutical CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Radiopharmaceutical CDMO Market Perspective (2021-2032)
  2. 3.2 Global Radiopharmaceutical CDMO Growth Trends by Region
  3. 3.2.1 Global Radiopharmaceutical CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Radiopharmaceutical CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Radiopharmaceutical CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Radiopharmaceutical CDMO Revenue by Players
  2. 4.1.1 Global Radiopharmaceutical CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Radiopharmaceutical CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Radiopharmaceutical CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Radiopharmaceutical CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Radiopharmaceutical CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Radiopharmaceutical CDMO Players, Product Type & Application
  8. 4.5 Global Radiopharmaceutical CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Radiopharmaceutical CDMO Market CR5 and HHI
  11. 4.6.3 2025 Radiopharmaceutical CDMO Tier 1, Tier 2, and Tier 3
5 Radiopharmaceutical CDMO Market Size by Type
  1. 5.1 Global Radiopharmaceutical CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Radiopharmaceutical CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Radiopharmaceutical CDMO Revenue Market Share by Type (2021-2032)
6 Radiopharmaceutical CDMO Market Size by Application
  1. 6.1 Global Radiopharmaceutical CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Radiopharmaceutical CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Radiopharmaceutical CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Almac
  2. 7.1.1 Almac Company Information
  3. 7.1.2 Almac Business Overview
  4. 7.1.3 Almac Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Almac Radiopharmaceutical CDMO Product Portfolio
  6. 7.1.5 Almac Recent Developments
  7. 7.2 AtomVie
  8. 7.2.1 AtomVie Company Information
  9. 7.2.2 AtomVie Business Overview
  10. 7.2.3 AtomVie Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AtomVie Radiopharmaceutical CDMO Product Portfolio
  12. 7.2.5 AtomVie Recent Developments
  13. 7.3 Cardinal Health
  14. 7.3.1 Cardinal Health Company Information
  15. 7.3.2 Cardinal Health Business Overview
  16. 7.3.3 Cardinal Health Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Cardinal Health Radiopharmaceutical CDMO Product Portfolio
  18. 7.3.5 Cardinal Health Recent Developments
  19. 7.4 Cyclotek
  20. 7.4.1 Cyclotek Company Information
  21. 7.4.2 Cyclotek Business Overview
  22. 7.4.3 Cyclotek Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Cyclotek Radiopharmaceutical CDMO Product Portfolio
  24. 7.4.5 Cyclotek Recent Developments
  25. 7.5 Eckert & Ziegler
  26. 7.5.1 Eckert & Ziegler Company Information
  27. 7.5.2 Eckert & Ziegler Business Overview
  28. 7.5.3 Eckert & Ziegler Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eckert & Ziegler Radiopharmaceutical CDMO Product Portfolio
  30. 7.5.5 Eckert & Ziegler Recent Developments
  31. 7.6 Seibersdorf Labor GmbH
  32. 7.6.1 Seibersdorf Labor GmbH Company Information
  33. 7.6.2 Seibersdorf Labor GmbH Business Overview
  34. 7.6.3 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Portfolio
  36. 7.6.5 Seibersdorf Labor GmbH Recent Developments
  37. 7.7 Evergreen Theragnostics
  38. 7.7.1 Evergreen Theragnostics Company Information
  39. 7.7.2 Evergreen Theragnostics Business Overview
  40. 7.7.3 Evergreen Theragnostics Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Evergreen Theragnostics Radiopharmaceutical CDMO Product Portfolio
  42. 7.7.5 Evergreen Theragnostics Recent Developments
  43. 7.8 Lantheus
  44. 7.8.1 Lantheus Company Information
  45. 7.8.2 Lantheus Business Overview
  46. 7.8.3 Lantheus Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lantheus Radiopharmaceutical CDMO Product Portfolio
  48. 7.8.5 Lantheus Recent Developments
  49. 7.9 Medi-Radiopharma
  50. 7.9.1 Medi-Radiopharma Company Information
  51. 7.9.2 Medi-Radiopharma Business Overview
  52. 7.9.3 Medi-Radiopharma Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Medi-Radiopharma Radiopharmaceutical CDMO Product Portfolio
  54. 7.9.5 Medi-Radiopharma Recent Developments
  55. 7.10 Minerva Imaging
  56. 7.10.1 Minerva Imaging Company Information
  57. 7.10.2 Minerva Imaging Business Overview
  58. 7.10.3 Minerva Imaging Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Minerva Imaging Radiopharmaceutical CDMO Product Portfolio
  60. 7.10.5 Minerva Imaging Recent Developments
  61. 7.11 NorthStar
  62. 7.11.1 NorthStar Company Information
  63. 7.11.2 NorthStar Business Overview
  64. 7.11.3 NorthStar Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 NorthStar Radiopharmaceutical CDMO Product Portfolio
  66. 7.11.5 NorthStar Recent Developments
  67. 7.12 ROTOP Pharmaka GmbH
  68. 7.12.1 ROTOP Pharmaka GmbH Company Information
  69. 7.12.2 ROTOP Pharmaka GmbH Business Overview
  70. 7.12.3 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Portfolio
  72. 7.12.5 ROTOP Pharmaka GmbH Recent Developments
  73. 7.13 Nucleus RadioPharma
  74. 7.13.1 Nucleus RadioPharma Company Information
  75. 7.13.2 Nucleus RadioPharma Business Overview
  76. 7.13.3 Nucleus RadioPharma Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Nucleus RadioPharma Radiopharmaceutical CDMO Product Portfolio
  78. 7.13.5 Nucleus RadioPharma Recent Developments
  79. 7.14 PharmaLogic
  80. 7.14.1 PharmaLogic Company Information
  81. 7.14.2 PharmaLogic Business Overview
  82. 7.14.3 PharmaLogic Radiopharmaceutical CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 PharmaLogic Radiopharmaceutical CDMO Product Portfolio
  84. 7.14.5 PharmaLogic Recent Developments
8 North America
  1. 8.1 North America Radiopharmaceutical CDMO Revenue (2021-2032)
  2. 8.2 North America Radiopharmaceutical CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Radiopharmaceutical CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Radiopharmaceutical CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Radiopharmaceutical CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Radiopharmaceutical CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Radiopharmaceutical CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Radiopharmaceutical CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Radiopharmaceutical CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Radiopharmaceutical CDMO Revenue by Country
  11. 8.6.1 North America Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Radiopharmaceutical CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Radiopharmaceutical CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Radiopharmaceutical CDMO Revenue (2021-2032)
  2. 9.2 Europe Radiopharmaceutical CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Radiopharmaceutical CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Radiopharmaceutical CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Radiopharmaceutical CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Radiopharmaceutical CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Radiopharmaceutical CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Radiopharmaceutical CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Radiopharmaceutical CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Radiopharmaceutical CDMO Revenue by Country
  11. 9.6.1 Europe Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Radiopharmaceutical CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Radiopharmaceutical CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Radiopharmaceutical CDMO Revenue (2021-2032)
  2. 10.2 China Radiopharmaceutical CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Radiopharmaceutical CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Radiopharmaceutical CDMO Revenue by Type (2027-2032)
  5. 10.3 China Radiopharmaceutical CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Radiopharmaceutical CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Radiopharmaceutical CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Radiopharmaceutical CDMO Revenue by Application (2027-2032)
  9. 10.5 China Radiopharmaceutical CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Radiopharmaceutical CDMO Revenue (2021-2032)
  2. 11.2 Asia Radiopharmaceutical CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Radiopharmaceutical CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Radiopharmaceutical CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Radiopharmaceutical CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Radiopharmaceutical CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Radiopharmaceutical CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Radiopharmaceutical CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Radiopharmaceutical CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Radiopharmaceutical CDMO Revenue by Country
  11. 11.6.1 Asia Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Radiopharmaceutical CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Radiopharmaceutical CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Radiopharmaceutical CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Radiopharmaceutical CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Radiopharmaceutical CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Radiopharmaceutical CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Radiopharmaceutical CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Radiopharmaceutical CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Radiopharmaceutical CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Radiopharmaceutical CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Radiopharmaceutical CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Radiopharmaceutical CDMO Revenue by Country
  11. 12.6.1 SAMEA Radiopharmaceutical CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Radiopharmaceutical CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Radiopharmaceutical CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst